Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL11255053 | 0.97 | MAPT (0.53) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11239265 | 0.87 | MAPT (0.57) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3612694 | 0.85 | MAPT (0.67) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11248461 | 0.83 | MAPT (0.55) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL11246181 | 0.82 | MAPT (0.53) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3606550 | 0.81 | MAPT (0.52) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3608636 | 0.81 | MAPT (0.51) | MAPTNPC1RAB9AGAANPSR1 | |
| Bromide SCHEMBL11253435 | 0.81 | MAPT (0.51) | MAPTNPC1RAB9AGAANPSR1 | |
| SCHEMBL3609002 | 0.80 | CFTR (0.60) | MAPTNPSR1MAPK1ALDH1A1MEN1 | |
| SCHEMBL3603750 | 0.80 | MAPT (0.55) | MAPTNPC1RAB9AGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | MAPT 2/4885NPC1 267/4885RAB9A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.